Reunion Neuroscience

Reunion Neuroscience is a clinical-stage pharmaceutical company developing treatments for underserved mental health conditions. The company’s lead asset, RE104, is a proprietary novel serotonergic psychedelic compound in development as a potential rapid and long-lasting antidepressant for patients suffering from postpartum depression and other mental health disorders. Reunion is also advancing the RE200 series, which includes compounds with more selective serotonin receptor activity and reduced psychoactivity, intended for more chronic treatment modalities and indications.